|60.59||+0.7000||+1.17%||Vol 13.41M||1Y Perf 209.24%|
|Jun 4th, 2020 16:00 DELAYED|
|- -%||- -%|
|Target Price||80.89||Analyst Rating||Strong Buy 1.39|
|Potential %||33.50||Finscreener Ranking||★★★+ 51.95|
|Insiders Trans % 3/6/12 mo.||-100/-99/-99||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-98/-98||Growth Ranking||★★+ 48.07|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-96/-96||Income Ranking||— -|
|Market Cap||22.49B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||65.00||Earnings Date||7th May 2020|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.37|
|EPS Growth Next 5 Years %||33.60|
|Avg. Weekly Volume||22.80M|
|Avg. Monthly Volume||33.84M|
|Avg. Quarterly Volume||21.45M|
Moderna Inc. (NASDAQ: MRNA) stock closed at 60.59 per share at the end of the most recent trading day (a 1.17% change compared to the prior day closing price) with a volume of 13.50M shares and market capitalization of 22.49B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 760 people. Moderna Inc. CEO is Stephane Bancel.
The one-year performance of Moderna Inc. stock is 209.24%, while year-to-date (YTD) performance is 209.76%. MRNA stock has a five-year performance of %. Its 52-week range is between 11.54 and 87, which gives MRNA stock a 52-week price range ratio of 65.00%
Moderna Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 13.91, a price-to-sale (PS) ratio of 439.06, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -26.11%, a ROC of -32.70% and a ROE of -32.76%. The company’s profit margin is -%, its EBITDA margin is -890.90%, and its revenue ttm is $52.57 Million , which makes it $0.14 revenue per share.
Of the last four earnings reports from Moderna Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.37 for the next earnings report. Moderna Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Moderna Inc. is Strong Buy (1.39), with a target price of $80.89, which is +33.50% compared to the current price. The earnings rating for Moderna Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Moderna Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Moderna Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 35.98, ATR14 : 6.41, CCI20 : -35.84, Chaikin Money Flow : 0.09, MACD : 2.71, Money Flow Index : 47.47, ROC : -15.46, RSI : 52.79, STOCH (14,3) : 35.38, STOCH RSI : 0.82, UO : 55.86, Williams %R : -64.62), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Moderna Inc. in the last 12-months were: Elizabeth G. Nabel (Sold 30 000 shares of value $1 980 000 ), Jennifer L. Lee (Sold 361 shares of value $9 866 ), Juan Andres (Option Excercise at a value of $2 840 156), Juan Andres (Sold 232 609 shares of value $12 156 586 ), Lorence H. Kim (Option Excercise at a value of $18 500 536), Lorence H. Kim (Sold 1 121 532 shares of value $57 488 366 ), Lori M. Henderson (Option Excercise at a value of $950 400), Lori M. Henderson (Sold 64 000 shares of value $4 480 000 ), Paul Sagan (Buy at a value of $999 989), Peter Barton Hutt (Option Excercise at a value of $12 000), Peter Barton Hutt (Sold 300 000 shares of value $5 799 000 ), Stephane Bancel (Sold 485 135 shares of value $14 886 829 ), Stephen Hoge (Sold 99 990 shares of value $3 352 931 ), Tal Zaks (Option Excercise at a value of $4 665 927), Tal Zaks (Sold 579 902 shares of value $31 355 637 )
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.